AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8147070
Drug: Nisoldipine (N)
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine (N) - 5 micrograms/kg bolus and 0.2 micrograms/kg/min continuous infusion
Trial: 3168559
Drug: Peroral intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral intestinal cleansing with 1.5 l cold electrolyte solution
Trial: 3168559
Drug: Rectal lavaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal lavaging
Trial: 11903525
Drug: Intravenous valproate
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous valproate 500 mg
Trial: 11903525
Drug: Intramuscular dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular dihydroergotamine 1 mg with metoclopramide 10 mg
Trial: 11903525
Drug: Intramuscular dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular dihydroergotamine
Trial: 25064429
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both BSSO and Le Fort I
Trial: 22801294
Drug: Pramipexole extended-release
RxNorm normalized name: pramipexole Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole extended-release (ER) once daily for 12 weeks, titrated to a maximum daily dose of 4.5 mg
Trial: 22801294
Drug: Pramipexole immediate-release
RxNorm normalized name: pramipexole Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole immediate-release (IR) 2 to 3 times daily for 12 weeks, titrated to a maximum daily dose of 4.5 mg
Trial: 22801294
Drug: Both ER
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ER and IR formulations
Trial: 20530645
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy (affected arm trained for 3 hours/day, non-affected arm restricted for 10 hours/day for two weeks)
Trial: 12224977
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod cream applied once daily for 7 days per week for 6 weeks
Trial: 12224977
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod cream applied once daily for 7 days per week for 12 weeks
Trial: 12224977
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (placebo) applied once daily for 3, 5, or 7 days per week, or twice daily for 7 days per week for 12 weeks
Trial: 7978560
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol treatments (1990)
Trial: 4577015
Drug: Extradural corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural corticosteroid injection
Trial: 31722314
Drug: Ropinirole hydrochloride
RxNorm normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ropinirole hydrochloride extended-release tablets
Trial: 11128567
Drug: Metoclopramide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (1.5 mg/kg, i.v.)
Trial: 26303665
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation in the anterior limbs of the internal capsule (ALIC)
Trial: 20028444
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% (50 microg/mL) ophthalmic solution applied nightly to eyelid margins
Trial: 20028444
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving triamcinolone acetonide (TAC) injections
Trial: 17894912
Drug: Ketamine (intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (intraoperative bolus of 0.15 mg kg‐1, followed by 0.5 mg per morphine 1 mg in a patient‐controlled analgesia device)
Trial: 12190090
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy with omeprazole for 3 months
Trial: 12190090
Drug: Placebo antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo antibiotics with omeprazole for 3 months
Trial: 12190090
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy in patients with antrum-predominant gastritis
Trial: 8625221
Drug: Octreotide 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 150 micrograms subcutaneously three times daily
Trial: 23649906
Drug: Acidic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidic saline (pH 3.3) injection
Trial: 23649906
Drug: Regular isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular isotonic saline injection
Trial: 23649906
Drug: Repeated injection
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated injection of acidic saline
Trial: 23649906
Drug: Injections (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections (both acidic and regular saline)
Trial: 20220040
Drug: L-DOPS +
RxNorm normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPS + Placebo (PLA)
Trial: 20220040
Drug: L-DOPS +
RxNorm normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPS + Entacapone (ENT)
Trial: 20220040
Drug: L-DOPS +
RxNorm normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPS + Carbidopa (CAR)
Trial: 19451574
Drug: Pulse cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse cyclophosphamide, 15 mg/kg every 2 to 3 weeks
Trial: 19451574
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral cyclophosphamide, 2 mg/kg per day
Trial: 11355559
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg twice a day, in 3 cycles of 6 weeks with 2 weeks between cycles)
Trial: 2506091
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (twice daily for 6 months)
Trial: 2506091
Drug: Glibenclamide and
RxNorm normalized name: Glibenclamide and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide and metformin combination therapy (for 6 months)
Trial: 25714579
Drug: Vitamin E,
RxNorm normalized name: GRx Vitamin E, topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin E, Metformin, or Placebo (Control) for 96 weeks
Trial: 15006954
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg qd for 5 days)
Trial: 15006954
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (amoxicillin [500 mg tid for 7 days], clarithromycin [500 mg bid for 7 days], or cefuroxime‐axetil [250 mg bid for 7 days])
Trial: 9422470
Drug: G‐CSF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 10 microg/kg/day + GM‐CSF 5 microg/kg/day (arm II)
Trial: 9422470
Drug: G‐CSF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 10 microg/kg/day alone (arm I)
Trial: 8486084
Drug: Propofol (0.2‐0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.2‐0.6 mg/kg)
Trial: 3322376
Drug: Epostane (progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epostane (progesterone synthesis inhibitor)
Trial: 25907821
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical treatment of COPD
Trial: 23294275
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg) in subjects with mild hepatic impairment
Trial: 23294275
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg) in subjects with moderate hepatic impairment
Trial: 18068522
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg enteric-coated tablet per day)
Trial: 18068522
Drug: Control (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (aspirin avoidance)
Trial: 16595222
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg twice daily) and clomiphene citrate (100 mg from the third day for 5 days)
Trial: 16595222
Drug: metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (500 mg three times daily) and clomiphene citrate (100 mg from the third day for 5 days)
Trial: 8613267
Drug: Brain natriuretic
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain natriuretic peptide (BNP) infusion
Trial: 8613267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ANP and BNP infusions
Trial: 1748538
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intravenous metronidazole
Trial: 1748538
Drug: 1.0 gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 gm intravenous metronidazole
Trial: 1748538
Drug: 2.0 gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 gm intravenous metronidazole
Trial: 1748538
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of metronidazole (1.0 gm and 2.0 gm)
Trial: 6412738
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of steroids and SCG
Trial: 21041836
Drug: Fluoridated artificial
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated artificial saliva (FS) at 1500 ppm fluoride treatment alone
Trial: 21041836
Drug: Fluoridated artificial
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated artificial saliva (FS) at 1500 ppm fluoride treatment combined with thermocycling (FS + Th)
Trial: 20430500
Drug: Folate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate (15 mg/d)
Trial: 20430500
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of folate (15 mg/d) and methylcobalamin (500 mug after each hemodialysis treatment 3 times weekly)
Trial: 19186852
Drug: NaF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF group (1450 mg/L sodium fluoride dentifrice)
Trial: 19186852
Drug: MFP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP group (1450 mg/L sodium monofluorophosphate dentifrice)
Trial: 9485231
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (15-g bolus + infusion of 1 g/h)
Trial: 9485231
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (10-g bolus + placebo infusion)
Trial: 2147014
Drug: Monophasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic preparation containing ethinylestradiol and desogestrel (M‐DG)
Trial: 2147014
Drug: Monophasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic preparation containing ethinylestradiol and gestodene (M‐GD)
Trial: 2147014
Drug: Triphasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic preparation of ethinylestradiol and levonorgestrel (T‐LN)
Trial: 17845881
Drug: Home-walking exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-walking exercise prescription
Trial: 9391992
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 micrograms) biweekly
Trial: 9391992
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (100 micrograms) biweekly
Trial: 8934730
Drug: Bolus single
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus single agent 5-FU
Trial: 30806758
Drug: IRI/CDDP (IRI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRI/CDDP (IRI, 60 mg/m2; CDDP, 30 mg/m2, q2w)
Trial: 30806758
Drug: IRI (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRI (150 mg/m2, q2w)
Trial: 22176808
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol (1 g/kg)
Trial: 22176808
Drug: 23.4% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23.4% hypertonic saline (0.686 mL/kg)
Trial: 19997098
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of a single dose of testosterone
Trial: 18996862
Drug: Experimental modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental modified starch therapy (100 g digestible starch)
Trial: 18996862
Drug: Traditional uncooked
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional uncooked cornstarch therapy (100 g)
Trial: 7436551
Drug: Dihydroergotamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine and heparin (DHE‐heparin) medication (2500 IU sodium heparin and 0.5 mg DHE, both given subcutaneously twice daily)
Trial: 7436551
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of heparin (5,000 IU of sodium heparin given subcutaneously thrice daily)
Trial: 25398970
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol (n = 42)
Trial: 25398970
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist protocol (n = 41)
Trial: 21373274
Drug: Self-testing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-testing of vaginal pH using test gloves, twice a week from 12th to 32nd week of gestation.
Trial: 20193613
Drug: Intranasal glucocorticoid
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glucocorticoid (INGS) for one year
Trial: 20193613
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) for 4 weeks
Trial: 17579637
Drug: 2500 mg
RxNorm normalized name: inulin 2500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2500 mg calcium diet
Trial: 17579637
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg calcium diet
Trial: 15514504
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g x kg(‐1) with approximately 1 L of water)
Trial: 3365983
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive use with alcohol consumption
Trial: 3365983
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive use without alcohol consumption
Trial: 23623526
Drug: Lansoprazole (detailed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (detailed dosage not provided)
Trial: 18166096
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy provided by the study
Trial: 12493134
Drug: Oral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatments for type II diabetes
Trial: 10742366
Drug: Theophylline (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (8 mg/kg)
Trial: 29914524
Drug: Multi-year implementation
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-year implementation intervention for AOUD treatment delivery
Trial: 29914524
Drug: Staff training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staff training and funding for medications
Trial: 24516879
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg calcifediol daily
Trial: 24516879
Drug: 140 μg
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 μg calcifediol weekly
Trial: 24516879
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus of 140 μg calcifediol
Trial: 24516879
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg vitamin D3 daily
Trial: 24516879
Drug: 140 μg
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 μg vitamin D3 weekly
Trial: 24516879
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus of 140 μg vitamin D3
Trial: 22456624
Drug: PEG 3
RxNorm normalized name: PEG 300
DrugBank: Polyethylene glycol 300 (DB11161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 3 L the day before and 1 L 3h before the procedure (split regimen)
Trial: 22456624
Drug: PEG 4
RxNorm normalized name: PEG 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 4 L the afternoon before colonoscopy (full regimen)
Trial: 21047442
Drug: Guided web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided web-based self-help intervention based on Problem Solving Treatment (PST) for 6 weeks
Trial: 15208052
Drug: Mifepristone, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone, 100 mg/day for 2 consecutive days every 30 days, from months 2-7 of implant use
Trial: 12126343
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy along with standard pharmacotherapy
Trial: 7857352
Drug: Pidotimod 800
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 800 mg administered orally twice a day for 30 days
Trial: 2510263
Drug: Sucralfate, 1
RxNorm normalized name: Sucralfate, 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, 1 g t.i.d.
Trial: 31750726
Drug: Vocal Music
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal Music Therapy (VMT) program for 12 weeks
Trial: 26645517
Drug: Coenzyme Q(10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q(10) 100 mg daily for 60 days
Trial: 18031592
Drug: Mixed fibre
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed fibre dose (3 g Plantago ovata husk and 1 g glucomannan) twice daily (b.i.d.)
Trial: 18031592
Drug: Mixed fibre
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed fibre dose (3 g Plantago ovata husk and 1 g glucomannan) three times daily (t.i.d.)
Trial: 18031592
Drug: Mixed fibre
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed fibre dose (b.i.d. and t.i.d.)
Trial: 15963388
Drug: glimepiride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride (1 to 6 mg)
Trial: 12502980
Drug: PPIA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPIA plus 0.5 mg/kg oral midazolam
Trial: 6849739
Drug: Atenolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25 mg oral)
Trial: 6849739
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg and 50 mg oral)
Trial: 6849739
Drug: Isoprenaline (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (sustained infusion)
Trial: 31924318
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Control, in diabetic patients)
Trial: 29049282
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (information and referrals)
Trial: 21946154
Drug: Protein-glucose solution
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-glucose solution (8% ¹³C‐enriched glucose and 2% milk protein concentrate)
Trial: 21946154
Drug: Glucose only
RxNorm normalized name: Glucose only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose only solution